Related Experiment Video
Updated: Jun 28, 2025

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
Published on: July 25, 2022
Virus-like particles derived from bacteriophage MS2 as antigen scaffolds and RNA protective shells
Antonina Naskalska1, Jonathan Gardiner Heddle1,2
1Malopolska Centre of Biotechnology, Jagiellonian University, Krakow, 30-392, Poland.
Abstract:
The versatile potential of bacteriophage MS2-derived virus-like particles (VLPs) in medical biotechnology has been extensively studied during the last 30 years. Since the first reports showing that MS2 VLPs can be produced at high yield and relatively easily engineered, numerous applications have been proposed. Particular effort has been spent in developing MS2 VLPs as protective capsules and delivery platforms for diverse molecules, such as chemical compounds, proteins and nucleic acids. Among these, two are particularly noteworthy: as scaffolds displaying heterologous epitopes for vaccine development and as capsids for encapsulation of foreign RNA. In this review, we summarize the progress in developing MS2 VLPs for these two areas.
Related Concept Videos
Viral Structure
Lytic Cycle of Bacteriophages
What are Viruses?
Leaky Scanning
Retrovirus Life Cycles
Intracellular Movement of Viruses and Bacteria

